

Journal of Pharmaceutical Research International

33(43B): 390-395, 2021; Article no.JPRI.73681 ISSN: 2456-9119 (Past name: British Journal of Pharmaceutical Research, Past ISSN: 2231-2919, NLM ID: 101631759)

Prevalence of Psoriasis Vulgaris and Its Associated Risk Factors in Pakistan

Syeda Ujala Sohail^{1*}, Nasima Iqbal², Ashok Kumar³, Sarwath Fatimee⁴, Ayesha Khan⁵ and Ruqaya Nangrejo⁶

¹Department of Dermatology, 2nd Affiliated Hospital, School of Xi'an Jiaotong University, China. ²Department of Pathology, Baqai Medical University, Karachi, Pakistan. ³Department of Anatomy, Shaheed Mohtarma Benazir Bhutto Medical College Liyari, Karachi, Pakistan. ⁴Department of Anatomy, Satima Jianah Dantel College, Karachi, Pakistan.

⁴Department of Anatomy, Fatima Jinnah Dental College, Karachi, Pakistan. ⁵Department of Ophthalmology, People's University of Health Sciences for Women, Nawabshah, Pakistan.

⁶Department of Physiology, Baqai Medical University, Karachi, Pakistan.

Authors' contributions

This work was carried out in collaboration among all authors. All authors read and approved the final manuscript.

Article Information

DOI: 10.9734/JPRI/2021/v33i43B32585 <u>Editor(s)</u>: (1) Dr. Takashi Ikeno, National Center of Neurology and Psychiatry, Japan. <u>Reviewers:</u> (1) Sunny, Chi Lik Au, Tung Wah Eastern Hospital, Hong Kong. (2) Gaurav Dubey, Uttar Pradesh University of Medical Sciences, India. Complete Peer review History: <u>https://www.sdiarticle4.com/review-history/73681</u>

Original Research Article

Received 30 June 2021 Accepted 10 September 2021 Published 14 September 2021

ABSTRACT

Aim: To find out the prevalence of psoriasis vulgaris and its associated risk factors.

Study Design: Descriptive cross-sectional.

Place and Duration of Study: Study was conducted at Rawalpindi Leprosy Hospital during January 2019 to December 2019.

Methodology: The diagnosed cases of Psoriasis Vulgaris (PsV) were included in the study. All the patients were investigated on the basis of an in depth Performa. The Performa include all the relevant clinical and family history of the patient along with the personal details. Data was analyzed by using Statistical Package for the Social Sciences (SPSS) version 20. All the numerical variables were presented as mean with standard deviation while categorical data as frequency and percentages. The association of risk factors with the Psoriasis was calculated by using the Chi-square test. p-value less than 0.05 was considered as significant.

*Corresponding author: E-mail: syedaujalasohail2@gmail.com;

Results: Mean age with standard deviation of patients was 34.7±14. Most of the diagnosed patients were male and below 40 years of age, only 4.2% cases were having positive family history of Psoriasis and found significant correlation. The frequency of onset of symptoms in adolescent was more as compared to childhood i.e. 95.3% and 4.7% respectively. Majority of psoriasis cases (65.3%) were from non-smoker group and having strong association with smoking. The frequency of arthritis among psoriasis patients was 23.7% and majority of the patients, who developed arthritis were those having age <40 year and were suffering from psoriasis since 5-10 years. **Conclusion:** Current study concluded that Psoriasis vulgar is having higher prevalence rate among male and below 40 years of age group. The results also suggested a strong association of severity of psoriasis with certain risk factors including family history, age of onset of symptoms, smoking and arthritis.

Keywords: Psoriasis vulgaris; smoking; arthritis.

1. INTRODUCTION

Psoriasis (PsV) is one of the most severe chronic skin diseases. It is characteristically lifelong disorder. There is no medication for the disease, but its symptoms can be minimized by different treatments [1]. It has five main types, which are inverse, guttate, plaque, erythrodermic and pustular. Out of these types, the most prevalent is plaque psoriasis, in which white and red shades of scaly lesions produce on epidermal layer. These lesions are produced by epidermal maturation and hyper proliferation [2, 3].

The global incidence of psoriasis is approximately 2%, but is more in developing countries, i.e. about 4.6%. Approximately two thirds of people are having milder form of psoriasis, with less than 3% of the cutaneous surface of the body is affected, but in severe form, there is wide involvement of skin [4]. Psoriasis affects men and women equally. Although it may begin at any age but two peaks in age groups are noted, one between age 20 and 30 years and another peak between ages 50 and 60 years [5]. That is why on the basis of age of onset, Psoriasis can be categorized in two types, one in patients with early-onset or Type I psoriasis (before the age of 40) and other is with late-onset or Type II psoriasis that occur after the age of 40 years [6].

Psoriasis is considered as a complex disease in which the interface between genetic and environmental risk factors are thought to play a main role. Focusing specifically environmental factors, these include infections mainly pharyngitis, smoking, trauma, stressful events and smoking [7, 8]. The most well-known comorbidity in psoriasis patients is arthritis (PsA), with incidence of 10–30% [9, 10]. So the aim of current study is to find out the prevalence of psoriasis vulgaris and its associated risk factors.

2. METHODOLOGY

Α descriptive cross-sectional study was conducted at Rawalpindi Leprosy Hospital during January 2019 to December 2019. Sample size was calculated by using OpenEpi calculator and was 190. The diagnosed cases of Psoriasis Vulgaris (PsV) were included in the study while those patients who were having any other associated disease were excluded to avoid bias in identifying the associated risk factors. All the patients were investigated on the basis of an in depth Performa. The Performa include all the relevant clinical and family history of the patient along with the personal details.

Data was analyzed by using Statistical Package for the Social Sciences (SPSS) version 20. All the numerical variables were presented as mean with standard deviation while categorical data as frequency and percentages. The association of risk factors with the Psoriasis was calculated by using the Chi-square test. p-value less than 0.05 was considered as significant.

3. RESULTS

Mean age with standard deviation of patients was 34.7±14. Maximum age noted was 89 years while minimum age was 4 years among cases. Regarding age of onset, patients were categorized as early-onset if they were first detected before the age of 40 year and late onset if they were diagnosed after 40 years. About 63.9% were above 40 years and 27.3% were below 40 years of age as presented in Fig. 1. Current results also found that most of the diagnosed patients were male and below 40 years of age.

Sohail et al.; JPRI, 33(43B): 390-395, 2021; Article no.JPRI.73681



Fig. 1. Frequency distribution of age of onset and gender affected

Looking over the demographic variables, only 4.2% cases were having positive family history of Psoriasis and found significant correlation. The frequency of onset of symptoms in adolescent was more as compared to childhood i.e. 95.3% 4.7% respectively. The cases and were distributed into two groups i.e. smoker and nonsmoker and results reported that majority of psoriasis cases (65.3%) were from non-smoker group. There were 66 out of 190 (34.7%) psoriasis patients who were smokers and about 50 (76%) of them had psoriatic plaques all over their body. The results suggested a strong association of smoking with severity of psoriasis. In current study the frequency of arthritis among psoriasis patients was 23.7% and majority of the patients, who developed arthritis were those having age <40 year and were suffering from psoriasis since 5-10 years. The demographic variables and their correlation with psoriasis is presented in Table 1.

On the basis of Body surface area affected among studied cases, mostly cases were those in which disease was diagnosed since 4-5 years and having severe form of psoriasis, as their whole body was affected (Fig. 2).

4. DISCUSSION

Psoriasis inclines to a chronic disease but, its course is changeable. There is mark variation in rigorousness over time, and remissions at some period are seen in 40% of cases [11]. Although it is not a life threatening disease but is related with morbidity. It ranges from mild form, having small hidden lesions that do not affect quality of life, to severe wide-spread skin lesions that leads to poor quality of life [12, 13].

Psoriasis lesion formed as outcome of hyper proliferative skin with impulsive keratinocyte maturation and partial cornification with nuclei preservation within the stratum corneum cells. Thus mitotic speed of the basal keratinocytes is increased resulting in thickening of the epidermis. The redness of the abrasions is due tortuous capillaries. There is also immune cells including dendritic cells and CD4+ chambers, which penetrate within the superior papillary dermis, and neutrophils and CD8+ Th cells inside the integument [14, 15]. There are several forms of psoriasis, the most common is Psoriasis Vulgaris (PsV), affecting almost 85 to 90% of all patients affected with psoriasis.

Clinically, it represents as elevated, well demarcated. erythematous inscriptions with supporter silvery scale. The skin areas most affected are the elbows, knees, sacral region and scalp. Other sites that could be affected are hands, feet, nails and the intertriginous areas (groins, axilla, umbilicus, retro-auricular folds [16]. The plaques are characterized by an oozing, red inflammation without scaling. A Swedish study reported that the ano-genital area was affected in 24 % of psoriasis patients [17]. Current study found that in majority of cases whole body was affected while very few of them reported with scalp involvement.

There are multiple risk factors, widely classified as genetic and environmental factors. Specifically focussing the environmental factors, include family history, history of smoking, infections mainly pharyngitis, trauma and any stressful event [18]. The role of smoking as a risk factor for psoriasis is well documented in literature. The role of smoking in the

Variables	Frequency	%	p-value	
Family History of psoriasis				
Yes	8	4.2%	0.03	
No	182	95.8%		
Onset of Symptoms				
Adolescent	181	95.3%	0.831	
Childhood	9	4.7%		
History of smoking				
Yes	66	34.7%	0.025	
No	124	65.3%		
Arthritis				
Yes	45	23.7%		
No	145	76.3%	0.008	

Table 1. Characteristics of study participants and their association with Psoriasis



Fig. 2. Frequency distribution of body surface area affected

pathogenesis of psoriasis was given by the Nurses' Health Study II that reported, for the first time, a strong correlation between smoking and incidence of psoriasis in a large populationbased prospective cohort study [19]. In their study, the risk of psoriasis was 1.8 for active smokers and 1.4 for passive smokers. Current results are in accordance with results reported in previous studies, that smoker are at high risk for developing disease [20]. Stressful life events are also thought to have an effect on course of psoriasis. In a case-control study, psoriasis subjects were more likely to involve a stressful event that preceded the onset and the exacerbation of the disease as compared to patients having other skin diseases [21].

The most well-known comorbidity in psoriasis patients is arthritis (PsA), with incidence of 10–30% [22]. It is considered by the progress of pain and joints tenderness next to ligaments and tendons [23]. PsA is equally common among

both genders and the onset of the disease is usually occurs between 30 to 55 years of age [24]. Current study found most of the patients who developed arthritis, were those having age <40 year and were suffering from psoriasis since 5-10 years so higher prevalence of arthritis among patients with severe form of the disease.

5. CONCLUSION

Current study concluded that Psoriasis vulgar is having higher prevalence rate among male and below 40 years of age group. The results also suggested a strong association of severity of psoriasis with certain risk factors including family history, age of onset of symptoms, smoking and arthritis.

CONSENT

Written informed consent was taken from the patients.

ETHICAL APPROVAL

Study got approval from the Ethics committee of PMAS–Arid Agriculture University Rawalpindi with a reference Number: ABPA00129.

COMPETING INTERESTS

Authors have declared that no competing interests exist.

REFERENCES

- 1. Armstrong AW, Read C. Pathophysiology, clinical presentation, and treatment of psoriasis: a review. Jama. 2020;323(19): 1945-60.
- Sarac G, Koca TT, Baglan T. A brief summary of clinical types of psoriasis. Northern clinics of Istanbul. 2016;3(1):79.
- 3. KO HC, JWA SW, Song M, KIM MB, KWON KS. Clinical course of guttate psoriasis: long-term follow-up study. The Journal of dermatology. 2010;37(10):894-9.
- 4. Gudjonsson JE, Elder JT. Psoriasis: epidemiology. Clinics in dermatology. 2007;25(6):535-46.
- Langley R, Krueger G, Griffiths C. Psoriasis: epidemiology, clinical features, and quality of life. Annals of the rheumatic diseases. 2005;64(suppl 2):ii18-ii23.
- Singh S, Kalb RE, de Jong EM, Shear NH, Lebwohl M, Langholff W, et al. Effect of age of onset of psoriasis on clinical outcomes with systemic treatment in the Psoriasis Longitudinal Assessment and Registry (PSOLAR). American journal of clinical dermatology. 2018;19(6):879-86.
- Chandran V, Raychaudhuri SP. Geoepidemiology and environmental factors of psoriasis and psoriatic arthritis. Journal of autoimmunity. 2010;34(3):J314-J21.
- Kamiya K, Kishimoto M, Sugai J, Komine M, Ohtsuki M. Risk factors for the development of psoriasis. International journal of molecular sciences. 2019;20(18):4347.
- Madland TM, Apalset EM, Johannessen AE, Rossebö B, Brun JG. Prevalence, disease manifestations, and treatment of psoriatic arthritis in Western Norway. The Journal of rheumatology. 2005;32(10):1918-22.
- Zachariae H, Zachariae R, Blomqvist K, Davidsson S, Molin L, Mørk C, et al. Quality of Life and Prevalence of Arthritis

Reported by 5,795 Members of the Nordic Psoriasis Associations. Acta dermato-venereologica. 2002;82(2).

- 11. Penzer-Hick R. Phototherapy for people with psoriasis-enhancing efficacy. Dermatological Nursing. 2017;16(2).
- De Korte J, Mombers FM, Bos JD, Sprangers MA, editors. Quality of life in patients with psoriasis: a systematic literature review. Journal of Investigative Dermatology Symposium Proceedings; 2004: Elsevier.
- Augustin M, Radtke MA. Quality of life in psoriasis patients. Expert review of pharmacoeconomics & outcomes research. 2014;14(4):559-68.
- 14. Visser MJ, Venter Ć, Roberts TJ, Tarr G, Pretorius E. Psoriatic disease is associated with systemic inflammation, endothelial activation, and altered haemostatic function. Scientific Reports. 2021;11(1):1-13.
- Ogawa E, Sato Y, Minagawa A, Okuyama R. Pathogenesis of psoriasis and development of treatment. The Journal of dermatology. 2018;45(3):264-72.
- Allen MH, Ameen H, Veal C, Evans J, Ramrakha-Jones V, Marsland A, et al. The major psoriasis susceptibility locus PSORS1 is not a risk factor for late-onset psoriasis. Journal of Investigative Dermatology. 2005;124(1):103-6.
- Inerot A, Enerbäck C, Enlund F, Martinsson T, Samuelsson L, Wahlström J, et al. Collecting a set of psoriasis family material through a patient organisation; clinical characterisation and presence of additional disorders. BMC dermatology. 2005;5(1):1-8.
- Boehncke W-H. Etiology and pathogenesis of psoriasis. Rheumatic Disease Clinics. 2015;41(4):665-75.
- Setty AR, Curhan G, Choi HK. Obesity, waist circumference, weight change, and the risk of psoriasis in women: Nurses' Health Study II. Archives of internal medicine. 2007;167(15):1670-5.
- 20. Richer V, Roubille C, Fleming P, Starnino T, McCourt C, McFarlane A, et al. Psoriasis and smoking: a systematic literature review and meta-analysis with qualitative analysis of effect of smoking on psoriasis severity. Journal of cutaneous medicine and surgery. 2016;20(3):221-7.
- 21. Naldi L, Chatenoud L, Linder D, Fortina AB, Peserico A, Virgili AR, et al. Cigarette smoking, body mass index, and stressful

life events as risk factors for psoriasis: results from an Italian case–control study. Journal of Investigative Dermatology. 2005;125(1):61-7.

- 22. Eder L, Haddad A, Rosen CF, Lee KA, Chandran V, Cook R, et al. The incidence and risk factors for psoriatic arthritis in patients with psoriasis: a prospective cohort study. Arthritis & rheumatology. 2016;68(4):915-23.
- 23. Gladman D, Antoni C, Mease P, Clegg D, Nash P. Psoriatic arthritis: epidemiology,

clinical features, course, and outcome. Annals of the rheumatic diseases. 2005;64(suppl 2):ii14-ii7.

24. Taylor W, Gladman D, Helliwell P, Marchesoni A, Mease P, Mielants H. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis & Rheumatism: Official Journal of College the American of Rheumatology. 2006;54(8):2665-73.

© 2021 Sohail et al.; This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Peer-review history: The peer review history for this paper can be accessed here: https://www.sdiarticle4.com/review-history/73681